How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

CLICK HERE FOR CME CREDIT

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY